Mathematical modeling of ovarian cancer treatments: Sequencing of surgery and chemotherapy

Journal of Theoretical Biology

Volumn 242, Issue 1, 2006, Pages 62-68

  Kohandel, M ^a,b   Sivaloganathan, S ^a,b   Oza, A ^b,c  

^a UNIVERSITY OF WATERLOO   (Canada)

^b FIELDS INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Mathematical modeling; Ovarian cancer; Tumor growth

Indexed keywords

CANCER; CHEMOTHERAPY; DISEASE TREATMENT; NUMERICAL MODEL; TUMOR;

ARTICLE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER SURGERY; HYPOTHESIS; MATHEMATICAL MODEL; OVARY CANCER; PRIORITY JOURNAL; THEORETICAL MODEL; THEORETICAL STUDY; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL DEATH; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 33746863746     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2006.02.001     Document Type: Article

References (43)

1. A randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian cancer, European Organization for Research and Treatment of Cancer, EORTC 55971, 2006.
2. Agarwal R., and Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3 7 (2003) 502-516
3. Bell D.R., and Wien L.M. Analysis and comparison of multimodal cancer treatments. IMA J. Math. Appl. Med. Biol. 18 (2001) 343-376
4. Bell D.R., and Wien L.M. Sequencing surgery, radiotherapy and chemotherapy: insights from a mathematical analysis. Breast Cancer Res. Treat. 74 (2002) 279-286
5. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol. Oncol. 38 2 (1990) 203-209
6. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 5 (2002) 1248-1259
7. Delgado G., Oram D.H., and Petrilli E.S. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol. Oncol. 18 3 (1984) 293-298
8. Fister K.R., and Panetta J.C. Optimal control applied to competing chemotherapeutic cell-kill strategies. SIAM J. Appl. Math. 63 (2003) 1954-1971
9. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42 (1975) 101-104
10. Guiot C., Degiorgis P.G., Delsanto P.P., Gabriele P., and Deisboeck T.S. Does tumor growth follow a "universal law"?. J. Theor. Biol. 225 2 (2003) 147-151
11. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61 4 (1983) 413-420
12. Heitjan D.F. Generalized Norton-Simon models of tumor growth. Statist. Med. 10 (1991) 1075-1088
13. Heuser L., Spratt J.S., and Polk H.C. Growth rates of primary breast cancers. Cancer (Phil) 43 (1979) 1888-1894
14. Holford N.H., and Sheiner L.B. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit. Rev. Bioeng. 5 (1981) 273-322
15. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., Ball H., and Berek J.S. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 4 (1994) 974-980
16. Hoskins P., Eisenhauer E., Vergote I., Dubuc-Lissoir J., Fisher B., Grimshaw R., Oza A., Plante M., Stuart G., and Vermorken J. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada clinical trials group study. J. Clin. Oncol. 18 (2000) 4038-4044
17. Jacob J.H., Gershenson D.M., Morris M., Copeland L.J., Burke T.W., and Wharton J.T. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 42 2 (1991) 146-150
18. Kayikcioglu F., Kose M.F., Boran N., Caliskan E., and Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 11 6 (2001) 466-470
19. Kuhn W., Rutke S., Spathe K., Schmalfeldt B., Florack G., von Hundelshausen B., Pachyn D., Ulm K., and Graeff H. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 10 (2001) 2585-2591
20. Laird A. Dynamics of tumor growth. Brit. J. Cancer 18 (1964) 490-502
21. Marcu L., Bezak E., Olver I., and van Doorn T. Tumour resistance to cisplatin: a modelling approach. Phys. Med. Biol. 50 (2005) 93-102
22. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., Wadler S., and Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 4 (2001) 1001-1007
23. Mazzeo F., Berliere M., Kerger J., Squifflet J., Duck L., D'Hondt V., Humblet Y., Donnez J., and Machiels J.P. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol. Oncol. 90 1 (2003) 163-169
24. Montalenti F., Sena G., Cappella P., and Ubezio P. Simulating cancer-cell kinetics after drug treatment: application to cisplatin on ovarian carcinoma. Phys. Rev. E 57 (1998) 5877-5887
25. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., Alvarez R.D., Kucera P.R., and Small J.M. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18 1 (2000) 106-115
26. Mutch D.G. Surgical management of ovarian cancer. Semin. Oncol. 29 (2002) 3-8
27. Norton A. A Gompertzian model of human breast cancer growth. Cancer Res. 48 (1988) 7067-7071
28. Norton L., and Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep. 61 (1977) 1307-1317
29. Norton L., and Simon R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70 (1986) 163-169
30. Norton L., Simon R., Brereton H.D., and Bogden A.E. Predicting the course of Gompertzian growth. Nature 264 (1976) 542-545
31. Panetta J.C. A mathematical model of breast and ovarian cancer treated with paclitaxel. Math. Biosci. 146 2 (1997) 89-113
32. Panetta J.C., and Adam J.A. A mathematical model of cycle-specific chemotherapy. Math. Comput. Model. 22 (1995) 67-82
33. Retsky M. Universal law of tumor growth. J. Theor. Biol. 229 (2004) 289
34. Retsky M.W., Swartzendruber D.E., Wardwell R.H., and Bame P.D. Is Gompertzian kinetics a valid description of individual tumor growth?. Med. Hypothesis 33 (1990) 95-106
35. Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C., Moore D.H., and Small J.M. Secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351 24 (2004) 2489-2497
36. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn EI E.I., and Thiel R.P. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol. Oncol. 72 1 (1999) 93-99
37. Skipper H.E., Schabel Jr. F.M., and Wilcox W.S. Experimental evaluation of potential anticancer agents XIII: on the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother. Rep. 35 (1964) 1-111
38. Speer J.F., Petrosky V.E., Retsky M.W., and Wardwell R.H. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res. 44 (1984) 4124-4130
39. Steed, H., Oza, A., Murphy, J., Laframboise, S., Lockwood, G., De Petrillo, D., Sturgeon, J., Rosen, B., A retrospective analysis of neoadjuvant platinum-based chemotherapy versus upfront surgery in advanced ovarian cancer, Int. J. Gynecol. Cancer, in press.
40. Surwit E., Childers J., Atlas I., Nour M., Hatch K., Hallum A., and Alberts D. Neoadjuvant chemotherapy for advanced ovarian cancer. Int. J. Gynaecol. Cancer 6 (1996) 356-361
41. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71 3 (1998) 431-436
42. Webb, G.F., 1992. A cell population model of periodic chemotherapy treatment. Biomed. Modeling Simulation, 83-92.
43. West G.B., Brown J.H., and Enquist B.J. A general model for ontogenetic growth. Nature 413 (2001) 628-631